JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES)

• Articles • Previous Articles     Next Articles

Concurrent chemoradiotherapy with docetaxel/cisplatin for local advanced non-small cell lung cancer

JIA Zheng-fei， FENG Yong, ZHONG Qin， XIA Xiao-tian   

  1. Department of Chemotherapy， Affiliated Huan′an First Hospital, Nanjing Medical University， Huai′an 223300， Jiangsu， China
  • Received:2008-05-25 Revised:1900-01-01 Online:2008-09-16 Published:2008-09-16
  • Contact: JIA Zheng-fei

PDF (PC)

484

Abstract: To evaluate the efficacy and side effects of concurrent radiotherapy and chemotherapy with docetaxel/cisplatin for local advanced non-small cell lung cancer (NSCLC). Methods A total of 76 patients with stage Ⅲ NSCLC were randomly divided into two groups: the docetaxel/cisplatin chemotherapy concurrent radiotherapy group(concurrent group) and the docetaxel/cisplatin chemotherapy sequential radiotherapy group(sequential group). In the two groups, the radiation method was the same, five times a week at 2 Gy per day up to a total dose of 60-70Gy. Chemotherapy consisted of docetaxel 40mg/m2 d1，8 and cisplatin 20mg/d, on day 1 and 5, lasting 21 days. The concurrent group received radiotherapy on day 1 of chemotherapy, while the sequential group received radiotherapy after 2 chemotherapy cycles. ResultsThe response rate in the concurrent group was 65.7% and 41.5% in sequential group (P<0.05). The complete response rate was 17.1% in the concurrent group and 7.3% in sequential group (P>0.05). The acute toxic effects such as radiation esophagitis were more severe in the concurrent group than in the sequential group (P<0.05). ConclusionConcurrent radiotherapy and chemotherapy with docetaxel/cisplatin is an effective regimen for advanced nonsmall cell lung cancer with increased but tolerable toxic effects.

Key words: Docetaxel, Cisplatin, Lung neoplasms, Concurrent chemoradiotherapy

CLC Number: 

  • R734.2
[1] WANG Yanan, LIANG Chuanjie, JIA Mengqi, YUAN Huiqing. Role of protein disulfide isomerase TMX1 in promoting chemotherapy resistance in lung cancer [J]. Journal of Shandong University (Health Sciences), 2023, 61(8): 31-39.
[2] XU Bing, LI Yong, LIU Ming, LIU Yonghui. Silencing PRRX1 gene expression enhances the sensitivity of prostate cancer resistant cell line PC-3/DTX to docetaxel [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 103-110.
[3] SUO Dongyang, SHEN Fei, GUO Hao, LIU Lichang, YANG Huimin, YANG Xiangdong. Expression and mechanism of Tim-3 in animal model of drug-induced acute kidney injury [J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 1-6.
[4] WANG Cong, ZHU Ling, WAN Yunyan, YAO Zhouhong, LI Dezhi, XU Xiaoting, XU Pengfei, LIN Dianjie. Therapeutic effect of different administration ways of recombinant human endostatin combined with cisplatin on Lewis lung cancer xenografts in mice [J]. Journal of Shandong University (Health Sciences), 2019, 57(5): 93-98.
[5] ZHANG Zhihui, LIU Yanguo, XIAO Fengqi, MA Daoxin, WANG Xiuwen. Effect of cisplatin on IL-6 expression in tumor mesenchymal stem cells and underlying mechanism of p38MAPK pathway [J]. Journal of Shandong University (Health Sciences), 2019, 57(3): 1-6.
[6] XUE Ting, WANG Liming, JIAO Jinwen, LI Yong, GUO Ailian, ZHAO Han. siRNA-mediated silencing of RRM2 in the treatment of epithelial ovarian cancer xenograft in nude mice [J]. Journal of Shandong University (Health Sciences), 2019, 57(10): 74-79.
[7] LÜ Huimin, ZHANG Mengwei, NIU Limin, ZENG Huiai, YAN Min. Efficacy and safety of single-agent domestic docetaxel in the treatment of advanced breast cancer [J]. Journal of Shandong University (Health Sciences), 2018, 56(1): 45-49.
[8] DING Changkuan, Jason Chen. Effects of proteasome inhibitor bortezomib combined with cisplatin on proliferation of human cervical cancer cells [J]. Journal of Shandong University (Health Sciences), 2018, 56(1): 70-75.
[9] DONG Wei, XING Naidong, LÜ Jiaju, LIU Shuai, SUN Liang, CAO Qingwei, DONG Yuhao, LIU Zhao, DING Sentai. The therapeutic efficacy of a potent KSP inhibitor S(MeO)TLC against docetaxel-resistant prostate cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(9): 23-30.
[10] ZHAO Ming, NIU Jie, LI Fangqin, WANG Aihong, PANG Qiuxia, CHEN Meini, ZHOU Lizhen, ZHAO Jumei. Effects of salinomycin combined with cisplatin on the proliferation and apoptosis of human gastric cancer cell line MKN-45 [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(5): 31-35.
[11] CUI Yong, ZHANG Rongxiang, WANG Fuli, WANG Guoying, FENG Jianlin, ZHANG Haixia. Clinical efficacy of BSD2000 deep hyperthermia combined with chemotherapy of TP regimen for advanced ovarian cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(7): 53-57.
[12] YANG Lu, LIU Yanguo, LI Jisheng, WANG Xiuwen. Effect of bufalin on chemosensitivity to cisplatin in non-small cell lung cancer and the underlying mechanisms [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(3): 6-11.
[13] ZHANG Min, WANG Xuefeng. Killing effect of apoptotic-tumor-cell-loaded dendritic cells on laryngeal carcinoma cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(7): 32-36.
[14] DING Huan1, SUN Ying1, LI Xiao-qing2, LI Li1. Effect of PARP inhibitor combined with Gemcitabine or Docetaxel on the  proliferation of androgen-independent prostate cancer cell line PC3 [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(1): 33-36.
[15] ZU Shan-shan1, MA Xiao-li1,2, JIA Yan-fei1,2, ZHAO Yun3, JIA Ying1, XIAO Dong-jie1,2, WANG Yun-shan1,2. Effects of down-regulated α5-nicotinic acetylcholine receptor expression on HIF-1α expression in lung cancer cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(9): 8-12.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd